FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
1,276 letters match. Newest first.
-
DrugsNatural Essentials, Inc.
FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.
High risk -
DrugsUmicore Argentina S.A.
CGMP/Active Pharmaceutical Ingredient (API)/Adulterated
-
DrugsShenzhen Benliju Biotech Co., Ltd.
FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.
High risk -
DrugsLGM Pharma Solutions, LLC
FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.
High risk -
DrugsNanjing Hanxin Pharmaceutical Technology Co. Ltd.
FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.
High risk -
DrugsUSV Private Limited
FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.
High risk -
DrugsChongqing Qiancan Technology Co., Ltd.
Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.
High risk -
DrugsTianjin Healthcare Medical Technology Co., Ltd.
Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.
High risk -
DrugsRonanRx, Inc. dba RonanRx
FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.
Low -
DrugsConroe Welding Supply, Inc.
FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).
High risk -
DrugsPritam International Private Limited
Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.
High risk -
DrugsGuangzhou Jiugong Research And Development Biotechnology Co., Ltd.
Guangzhou Jiugong, an OTC drug maker, used a color additive FDA cancelled in 1976 and fell short of CGMP.
High risk -
DrugsGuangdong Bisutang Biotechnology Co., Ltd.
Guangdong Bisutang Biotechnology refused FDA records requests for OTC drugs and used a cancelled color additive in sunscreen.
High risk -
DrugsNew Green Nutrition Inc.
FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.
High risk -
DrugsOng Tien USA LLC
FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.
High risk -
DrugsBella’s Nutri Shop Inc.
Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.
High risk -
DrugsJing Cheong Asia Inc. dba New York Tong Ren Tang
New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.
High risk -
DrugsPhuoc Loc Tho Herbals, Inc.
FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.
High risk -
DrugsNatuzem
FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.
High risk -
DrugsGuangdong Bangze Medicine Co., Ltd.
CGMP/Finished Pharmaceuticals/Adulterated/OTC
-
DrugsBest Chinese Medicines LLC
FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.
High risk -
DrugsNorthland Nuclear Medicine, LLC
FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.
High risk -
DrugsSanrace Biotechnology Co., Ltd.
FDA warns Sanrace Biotechnology over CGMP failures in OTC drugs, including missing identity tests and no process validation.
High risk -
DrugsTSP Solutions Pte. Ltd.
FDA warns Singapore OTC drug maker TSP Solutions over missing release testing and component identity checks for sunscreens.
High risk -
DrugsAmgen Inc.
FDA says an Amgen promotional video for the cancer drug Vectibix is false and misleading because it leaves out all risk information.
Medium -
DrugsRohto Pharmaceutical Co., Ltd.
FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.
High risk -
DrugsZhejiang Gaorong Cosmetic Co., Ltd.
FDA cited Zhejiang Gaorong Cosmetic for OTC drug CGMP violations in component testing and quality unit oversight.
High risk -
DrugsSignature Formulations LLC
FDA warns Signature Formulations about contaminated contract-manufactured drug products and cross-contamination at its Phoenix facility.
High risk -
DrugsBaxter International Inc.
Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.
High risk -
DrugsSnugZ USA, Inc.
SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.
High risk -
DrugsEurofins SF Analytical Laboratories, Inc.
FDA warned Eurofins SF Analytical Laboratories, a contract drug-testing lab, that it kept incomplete microbial test records and skipped required investigations.
High risk -
DrugsLovelace Biomedical Research Institute
Lovelace Biomedical's quality unit failed to ensure final drug study reports matched raw data, FDA says.
Medium -
DrugsSilgan Dispensing Systems
Silgan Unicep Packaging was cited for manufacturing quality failures and unapproved new drugs after invalidated microbial tests and a fungal recall.
High risk -
DrugsHanlim Pharm Co., Ltd.
FDA warned Hanlim Pharm over serious sterile manufacturing violations, including poor aseptic practices and airflow problems, at its South Korea plant.
High risk -
DrugsJiangmen Shuizirun Sanitary Articles Co., Ltd.
FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.
High risk -
DrugsSCA Pharmaceuticals, LLC
SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.
High risk -
DrugsWalmart, Inc.
Walmart sold three unapproved drugs for genital herpes and sores on walmart.com, FDA says.
High risk -
DrugsThe Platinum Healthcare LLC
The Platinum Healthcare LLC sells unapproved new drugs 'Sycosis' and 'Syphillinum' online for STIs, FDA warns.
High risk -
DrugsAidance Scientific, Inc.
FDA: Aidance Scientific's Terragen HG Formula, sold for genital sores, is an unapproved new drug.
High risk -
DrugsGraceful Touch, LLC
Graceful Touch marketed 'Herpes B Gone' cream as an unapproved new drug for herpes and STI symptoms, FDA says.
High risk -
DrugsAmazon.com, Inc.
FDA warns Amazon over nine unapproved drugs sold on its website for genital herpes and STI symptoms.
High risk -
DrugsOrganiCare, LLC / OrganiCare Nature’s Science, LLC
FDA told OrganiCare of Austin, Texas that its HClear for him and FemiClear Genital Herpes Symptoms ointments are unapproved new drugs.
High risk -
DrugsTerramed
FDA warned Terramed that four STI-related washes and ointments are unapproved new drugs sold online.
High risk -
DrugsBioactive Services USA, LLC / Herstat Inc.
FDA warns Bioactive Services/Herstat that Herstat GST is an unapproved new drug for genital sores.
High risk -
DrugsDesBio/Deseret Biologicals, Inc.
FDA says DesBio’s CHLA:10M, sold online for Chlamydia symptoms, is an unapproved new drug.
High risk -
DrugsRoyceDerm LLC
FDA says RoyceDerm LLC marketed Herpes Relief Cream, an unapproved new drug, for herpes symptoms on its website.
High risk -
DrugsCheap Medicine Shop/www.cheapmedicineshop.com
FDA warned India-based website Cheap Medicine Shop for selling unapproved, misbranded injectable semaglutide to U.S. consumers.
High risk -
DrugsOnline Generic Medicine/www.onlinegenericmedicine.com
FDA warned Online Generic Medicine that its website sells unapproved, misbranded injectable semaglutide to U.S. consumers.
High risk -
DrugsTCI Co., Ltd BioCosme PABP BRANCH
FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.
High risk -
DrugsPine Pharmaceuticals, LLC
FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.
High risk